Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Charles Serhan
Brigham and Women's Hospital, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Resolvyx Pharmaceuticals
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
The goal of this research is to harness specialized proresolving mediators (SPMs) and their bioactive SPM-sulfido conjugates for resolution pharmacology. The research will provide data on the protective actions and mechanisms for specialized pro-resolving mediators. The research involves IP (resolvins) licensed to a company called Resolvyx Pharmaceuticals. Resolvyx is a private company that is focused on developing an entirely new class of medicines called resolvins. Dr. Serhan is a scientific founder of Resolvyx and has founder’s equity. He is also an inventor of resolvin and protectin IP that is licensed to Resolvyx. The institution reviewed the research and the financial interest and noted that the results of this research grant may further validate the therapeutic potential of resolvins and thus benefit Resolvyx. Positive results may also help the company as it seeks to find strategic partners for its resolvins therapeutics programs. Given Dr. Serhan has a significant financial interest in the company (private equity), the reviewers concluded that the financial interest in Resolvyx creates a financial conflict of interest (COI) with the research.
Resolution Mechanisms in Acute Inflammation: Resolution Pharmacology
To improve patient care, a goal of this program project is to harness specialized pro- resolving mediators (SPMs) and their bioactive SPM-sulfido conjugates that we recently discovered for resolution pharmacology. This is a novel therapeutic approach to better treat human diseases and tissue injury where uncontrolled infectious inflammation and tissue regeneration are important. The potential for resolution pharmacology as a new therapeutic approach could diminish the healthcare consequences of uncontrolled prolonged infectious inflammation and tissue damage.
Filed on April 01, 2016.
Tell us what you know about Charles Serhan's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Charles Serhan filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Charles Serhan | Brigham and Women's Hospital | Conflict of Interest | Resolvyx | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.